FOXO4-DRI: A Senescent-Cell Research Question
AXON Research Institute • AXON Peptide affiliation
Educational draft • Scientific + legal review pending
Silent film with full on-screen captions. Conceptual illustrations, not molecular structures.

Some damaged cells enter senescence and remain in tissue. FOXO4-DRI was designed to test whether a protein interaction helps certain senescent cells stay alive. In the original study, the peptide disrupted an interaction involving FOXO4 and p53. Selected senescent cells then underwent programmed cell death in laboratory experiments. Researchers also reported tissue-function changes in mouse models of aging and chemotherapy-related injury. These experiments tested particular models, not anti-aging treatment in people. A later study reported lung-circulation changes and loss of lung blood-vessel lining cells in mice engineered to overexpress the serotonin transporter and given FOXO4-DRI. This raises a model-specific safety concern; it does not quantify risk in people. That distinction matters. A mechanism and animal results do not establish human rejuvenation, long-term safety or which people might benefit. Those remain separate research questions.

END CARD
Educational draft. Not medical advice. Sources and limitations accompany this film.

SOURCES
[1] Baar et al. (2017): Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging
https://pubmed.ncbi.nlm.nih.gov/28340339/
Primary cell and mouse study; indexed abstract and study record reviewed

[2] Born et al. (2023): Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression
https://pubmed.ncbi.nlm.nih.gov/36515093/
Primary preclinical study; indexed original abstract reviewed

EVIDENCE LIMITATIONS
Do not turn cell selectivity in these experiments into universal selectivity or safety.
Do not describe the mouse findings as human age reversal or lifespan extension.
Do not infer that removing every senescent cell is desirable.
Born et al. (2023) reported the FOXO4-DRI finding in serotonin-transporter-overexpressing mice. Do not transfer effect sizes or findings from the paper’s other senolytic interventions or animal models to FOXO4-DRI.
The mouse pulmonary safety signal does not establish its frequency, severity or causal risk in humans.

TOPIC INVENTORY PROVENANCE (not reused audiovisual media)
Original topic requested by Nina; not attributed to an additional verified Facebook video.